You are viewing the site in preview mode

Skip to main content

Advertisement

Table 5 Antibiotic susceptibility results of extended spectrum beta lactamase (ESBL) and non-ESBL Klebsiella pneumoniae isolates

From: Klebsiella pneumoniae bloodstream infections at a South African children’s hospital 2006–2011, a cross-sectional study

Antibiotic Number of resistant isolates
Non-ESBL KP ESBL KP
n/N (%) n/N (%)
Ampicillin 71/71 (100) 339/339 (100)
Co-amoxyclav 5/71 (7.1) 280/331 (84.6)
Cefotaxime 0/71 (0) 339/339 (100)
Ceftazidime 0/71 (0) 339/339 (100)
Cefepime 0/71 (0) 339/339 (100)
Ciprofloxacin 0/71 (0) 142/339 (41.9)
Cotrimoxazole 18/71 (25.4) 313/339 (92.3)
Amikacin 0/71 (0) 98/339 (28.9)
Gentamicin 4/71 (5.6) 319/338 (94.4)
Piperacillin-Tazobactam 2/67 (3.0) 136/282 (48.2)
Ertapenem 0/67 (0) 2/338 (0.6)
Imipenem 0/71 (0) 0/338 (0)
Meropenem 0/71 (0) 0/338 (0)
  1. KP Klebsiella pneumoniae, ESBL KPBSI Extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae bloodstream infection, co-amoxyclav amoxicillin-clavulanic acid co-formulation, n/N stratum specific proportions